Christopher Manz, MD, MSHP

Christopher Manz, MD, MSHP

Medical Oncology

Contact Information

Office Phone Number



Christopher Manz, MD, MSHP

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.



Instructor in Medical Oncology, Harvard Medical School


Clinical Interests


Board Certification

  • Internal Medicine


  • University of Pennsylvania


  • Hospital of the University of Pennsylvania

Medical School

  • Duke University School of Medicine

Recent Awards

  • Penn Department of Medicine Measey Physician Scientist Fellowship Award
  • ASCO Conquer Cancer Young Investigator Award


    Health services research, cancer disparities, cancer care delivery innovation, payment policy
    Dr. Manz investigates cancer care delivery and payment policy and how they contribute to disparities in cancer outcomes, with the goal of informing policies that can reduce cancer care disparities.
    Dr. Manz’s research on payment policy focuses on how the way that we pay for drugs and services affects cancer outcomes. His recent and current work explores how Medicare policies that pay for new cancer therapies in the Oncology Care Model and the New Technology Add-on Payment affects disparities in patient access to new therapies. He is also examining how models for distributing and reimbursing expensive cancer drugs administered in doctor’s offices affect patient out of pocket costs and drug prices.
    Dr. Manz has also investigated novel applications of machine learning to prompt oncology clinicians to have Serious Illness Conversations with their patients. His work has demonstrated that combining machine-learning generated mortality predictions with behavioral nudges to oncology clinicians can increase the number of Serious Illness Conversations that patients have with their oncology team, which may ensure that patients receive goal-concordant care near the end of life.  This work may improve the value of care that oncologists provide for their patients.


      • Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e431352. View in: Pubmed

      • Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial. J Med Internet Res. 2024 May 17; 26:e51059. View in: Pubmed

      • Are linchpin oncologists keeping the wheels from falling off cancer care? J Natl Cancer Inst. 2024 Feb 08; 116(2):180-182. View in: Pubmed

      • Creating a culture for change: Lessons from behavioral economics and complexity science to increase serious illness conversations for patients with cancer. Curr Probl Cancer. 2023 10; 47(5):101020. View in: Pubmed

      • Remote Patient-Reported Outcomes and Activity Monitoring to Improve Patient-Clinician Communication Regarding Symptoms and Functional Status: A Randomized Controlled Trial. JCO Oncol Pract. 2023 12; 19(12):1143-1151. View in: Pubmed

      • Cancer equity for those impacted by mass incarceration. J Natl Cancer Inst. 2023 10 09; 115(10):1128-1131. View in: Pubmed

      • Leveraging Goals of Care Interventions to Deliver Personalized Care Near the End of Life. JAMA Oncol. 2023 08 01; 9(8):1029-1030. View in: Pubmed

      • Cancer Screening Rates and Outcomes for Justice-Involved Individuals: A Scoping Review. J Correct Health Care. 2023 Jun; 29(3):220-231. View in: Pubmed

      • Long-term Effect of Machine Learning-Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023 03 01; 9(3):414-418. View in: Pubmed

      • Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2249720. View in: Pubmed

      • Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies. JAMA Netw Open. 2022 09 01; 5(9):e2234161. View in: Pubmed

      • Oncologist Perceptions of Algorithm-Based Nudges to Prompt Early Serious Illness Communication: A Qualitative Study. J Palliat Med. 2022 11; 25(11):1702-1707. View in: Pubmed

      • Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncol Pract. 2022 09; 18(9):e1447-e1453. View in: Pubmed

      • Oncologist phenotypes and associations with response to a machine learning-based intervention to increase advance care planning: Secondary analysis of a randomized clinical trial. PLoS One. 2022; 17(5):e0267012. View in: Pubmed

      • Patient and clinician nudges to improve symptom management in advanced cancer using patient-generated health data: study protocol for the PROStep randomised controlled trial. BMJ Open. 2022 05 12; 12(5):e054675. View in: Pubmed

      • Clinician perspectives on machine learning prognostic algorithms in the routine care of patients with cancer: a qualitative study. Support Care Cancer. 2022 May; 30(5):4363-4372. View in: Pubmed

      • Impact of Behavioral Nudges on the Quality of Serious Illness Conversations Among Patients With Cancer: Secondary Analysis of a Randomized Controlled Trial. JCO Oncol Pract. 2022 04; 18(4):e495-e503. View in: Pubmed

      • Automated Text-Based Symptom Monitoring With Rapid Clinician Triage for Patients With Cancer and Suspected or Confirmed COVID-19. JCO Clin Cancer Inform. 2021 10; 5:1134-1140. View in: Pubmed

      • Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries. J Manag Care Spec Pharm. 2021 Oct; 27(10):1457-1468. View in: Pubmed

      • Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review. Cancer Med. 2021 10; 10(20):7277-7288. View in: Pubmed

      • Racial Disparities in Colorectal Cancer Recurrence and Mortality: Equitable Care, Inequitable Outcomes? J Natl Cancer Inst. 2021 06 01; 113(6):656-657. View in: Pubmed

      • Combining Machine Learning Predictive Algorithms With Behavioral Nudges to Increase Rates of Serious Illness Conversations in Patients With Cancer-Reply. JAMA Oncol. 2021 05 01; 7(5):782. View in: Pubmed

      • Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Oncol. 2020 Dec 01; 6(12):e204759. View in: Pubmed

      • Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer. JAMA Oncol. 2020 Nov 01; 6(11):1723-1730. View in: Pubmed

      • The Changing Characteristics of Technologies Covered by Medicare's New Technology Add-on Payment Program. JAMA Netw Open. 2020 08 03; 3(8):e2012569. View in: Pubmed

      • Integrating machine-generated mortality estimates and behavioral nudges to promote serious illness conversations for cancer patients: Design and methods for a stepped-wedge cluster randomized controlled trial. Contemp Clin Trials. 2020 03; 90:105951. View in: Pubmed

      • Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies. J Clin Oncol. 2020 02 10; 38(5):384-387. View in: Pubmed

      • Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer. JAMA Netw Open. 2019 10 02; 2(10):e1915997. View in: Pubmed

      • Mind the gap: how vulnerable patients fall through the cracks of cancer quality metrics. BMJ Qual Saf. 2020 02; 29(2):91-94. View in: Pubmed

      • Getting in sync with adherence to endocrine therapy in breast cancer. Cancer. 2019 11 15; 125(22):3917-3920. View in: Pubmed

      • Marketing to physicians in a digital world. N Engl J Med. 2014 Nov 13; 371(20):1857-9. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Ave Dana Building 1111 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Ave Dana Building 1111 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Christopher Manz, MD, MSHP

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights